Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + Disitamab Vedotin for BCG-unresponsive bladder carcinoma in situ
ChiCTR2300079192Phase 2Recruiting
- Sponsor
- The Second Hospital of Tianjin Medical University
- Start
- Dec 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab and disitamab vedotin in Bladder cancer in situ (CIS) and non-muscle-invasive bladder cancer (NMIBC), sponsored by The Second Hospital of Tianjin Medical University. Primary endpoint: Complete response rate. Started Dec 2023; status: recruiting.
02
Drugs
tislelizumabdisitamab vedotin
03
Conditions
Bladder cancer in situ (CIS)non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on ChiCTR2300079192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300079192.